• Bay 11-7085: NF-κB Mechanism and Evidence

  2026-10-04

  Bay 11-7085 is a supplier-described NF-κB activation inhibitor and chemical probe for studying inflammatory signaling, cell-cycle regulation, and apoptosis. Its reported pharmacology is useful for pathway-focused research, but model-specific findings should not be interpreted as proof of clinical efficacy or pathway exclusivity.

• PPP1R3G Activates RIPK1 in Cell Death Signaling

  2026-10-03

  The Nature Communications study identifies PPP1R3G and PP1γ as a phosphatase module that removes inhibitory RIPK1 phosphorylation and promotes RIPK1-dependent apoptosis and type I necroptosis. Its genetic, biochemical, pharmacological, and mouse-model evidence connects RIPK1 activation with TNF-driven inflammatory pathology while defining important limits for translation beyond the tested systems.

• (5Z)-7-Oxozeaenol: TAK1 Inhibitor Workflows

  2026-10-02

  Build reproducible inflammation and metabolic-stress assays with (5Z)-7-Oxozeaenol, a selective TAK1 inhibitor that connects proximal kinase control to NF-κB, JNK/p38 MAPK, and COX-2 outputs. This guide distinguishes established product benchmarks from practical starting conditions and shows how to interpret TAK1 activity alongside the AMPK–SQSTM1–NRF2 stress response.

• LY294002: Reversible PI3K Pathway Inhibition

  2026-10-01

  LY294002, also known as 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, is a cell-permeable, reversible class I PI3K inhibitor. It is used to interrogate PI3K/Akt/mTOR signaling, apoptosis, autophagy, and ovarian carcinoma research, while its BET bromodomain activity requires careful interpretation.

• (5Z)-7-Oxozeaenol TAK1 Workflows

  2026-10-01

  (5Z)-7-Oxozeaenol enables targeted interrogation of TAK1-dependent inflammatory signaling and its connection to metabolic stress adaptation. This practical guide covers cell-based workflows, AMPK–SQSTM1 assay design, controls, and troubleshooting for interpreting NF-κB, JNK/p38 MAPK, and COX-2 responses.

• Troglitazone Workflows for PPARγ and TAM Research

  2026-09-30

  Troglitazone gives researchers a practical PPARγ-centered perturbation tool for connecting lipid and glucose metabolism with macrophage and renal carcinoma assays. This guide combines formulation, dose-finding, SPP1-reporter workflows, troubleshooting, and evidence-based boundaries for translating metabolic signaling into tumor-microenvironment research.

• Bromodomain Inhibitor (+)-JQ1 and Ferroptosis

  2026-09-30

  Explore how Bromodomain Inhibitor, (+)-JQ1 converts BRD4 inhibition into a ferroptosis-sensitizing strategy through ROS accumulation and FSP1 regulation. This article translates recent mechanistic findings into practical assay and interpretation decisions.

• Gastric Cancer Assembloids: Tumor–Stroma Drug Response

  2026-09-29

  The reference study develops patient-derived gastric cancer assembloids by combining tumor organoids with matched stromal cell subpopulations. Its findings show that stromal composition changes gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor biology, resistance, and personalized treatment.

• Prednisone in Immune Assays: G1 Arrest to Readouts

  2026-09-29

  Prednisone is a synthetic corticosteroid used to model lymphocyte suppression, G1 arrest, cytokine signaling, and apoptosis. This guide adds a matrix-aware assay strategy inspired by recent LC–MS/MS research on digestive transformations, helping researchers connect compound handling with more interpretable immune-cell data.

• (S)-(+)-Dimethindene maleate: M2 Workflow

  2026-09-28

  (S)-(+)-Dimethindene maleate is a research reagent for probing M2 muscarinic receptor antagonism while accounting for additional histamine H1 activity. This guide covers salt-aware preparation, controls, and QC for autonomic, cardiovascular, and respiratory assays; it is not intended for diagnostic, therapeutic, or clinical use.

• Bromodomain Inhibitor, (+)-JQ1: Evidence & Use

  2026-09-28

  Bromodomain Inhibitor, (+)-JQ1 is a BET bromodomain inhibitor that competitively targets acetyl-lysine binding sites, including BRD4 bromodomains 1 and 2. Research evidence connects JQ1 treatment with reduced KLF6 expression and adipogenesis in human adipose-derived stem cells, while other reported applications remain model-specific and preclinical.

• Grazoprevir hydrate for Reliable HCV Assays

  2026-09-27

  A scenario-driven guide to using Grazoprevir hydrate (SKU C8713) in HCV antiviral and cell-viability workflows. It explains assay controls, DMSO compatibility, genotype-specific potency context, and practical criteria for evaluating research compounds without confusing antiviral activity with cytotoxicity.

• Machine Learning Predicts mRNA Vaccine LNP Performance

  2026-09-26

  A LightGBM model trained on 325 mRNA vaccine lipid nanoparticle formulations predicted IgG responses and highlighted ionizable-lipid substructures associated with performance. Mouse experiments and molecular dynamics provided complementary checks, illustrating how computational screening can guide formulation research without replacing experimental validation.

• Palomid 529: Testing the RCN2–AKT Axis in ESCC

  2026-09-25

  Explore how Palomid 529 (P529), a dual mTORC1/2 inhibitor, can help test signaling hypotheses raised by new ESCC research. This article separates established RCN2 biology from unvalidated drug hypotheses and offers a practical framework for pathway-focused experiments.

• SNAI1–PIK3R2/p-EphA2 Signaling in Thymic Tumors

  2026-09-25

  A 2024 study identifies SNAI1 as a driver associated with invasiveness in thymic epithelial tumors and links it to EMT and cancer stem cell-like features. Combining tumor-expression analyses with functional experiments, the authors propose that SNAI1 transcriptionally regulates PIK3R2, which interacts with phosphorylated EphA2 and supports downstream GSK3β/β-catenin signaling.

8174 records 1/545 page Next 12345 下5页 Last page